COYA 101

About Coya Therapeutics

Coya Therapeutics' mission is to develop novel Treg-enhancing therapies to address chronic inflammatory diseases driven by immune dysfunction. The company has achieved key milestones, including Health Canada CTA acceptance for a Phase 2 ALS trial and U.S. FDA IND clearance for Frontotemporal Dementia for its lead candidate COYA 302. Its strategy leverages a diversified platform of biologics, exosomes, and cell therapies to target multiple indications and patient populations. Recent private financing provides capital to advance its clinical programs.

Therapeutic Areas